A practical reference on GHRH receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-21. Anything still debated is marked as such rather than presented as settled.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
== Structure == Most self-assembling molecules are amphiphilic, meaning they have both hydrophobic and hydrophilic character. Peptide amphiphiles are a class of molecules consisting of either hydrophobic and hydrophilic peptide sequences, or a hydrophilic peptide with an attached hydrophobic group, which is usually an alkyl chain. The structure of a peptide amphiphiles has four key domains. Firstly there is a hydrophobic section, typically an alkyl chain. Secondly there is the peptide sequence which forms intermolecular hydrogen bonding. Thirdly there is a section of charged amino acid residues to enhance the solubility of the peptide in water. The final structural feature allows the peptide to interact with biomolecules, cells, or proteins, and this is often through epitopes (part of antigens recognised by the immune system). As with other amphiphilic molecules, above a critical aggregation concentration peptide amphiphiles associate through non-covalent interactions to form ordered assemblies of different sizes, from nanometres to microns. Molecules that contain both polar and non-polar elements minimise unfavourable interactions with the aqueous environment via aggregation, which allows the hydrophilic moieties to be exposed to the aqueous environment, and the hydrophobic moieties to be protected. When aggregation occurs, a variety of assemblies can be formed depending on many parameters such as concentration, pH, temperature and geometry. The assemblies formed range from micelles to bilayer structures, such as vesicles, as well as fibrils and gels.
L-aspartate-4-semialdehyde + NADP+ + phosphate Once L-aspartate-4-semialdehyde is synthesized, the molecule can then progress down a number of pathways. One possible pathway requires L-aspartate-4-semialdehyde to undergo a reaction catalyzed by the enzyme dihydrodipicolinate synthase in order to form the molecule dihydrodipicolinate. This reversible chemical reaction is shown below:
Deborah Kay Dunn-Walters FMedSci (born September 1963) is a British immunologist who is Professor of Immunology and Associate Dean for Research and Innovation at the University of Surrey. Her research considers B-cell development in healthy ageing and in disease, particularly from the viewpoint of antibody repertoires. During the COVID-19 pandemic, Dunn-Walters focussed on mapping responses to SARS-CoV-2 infection and the development of single cell analyses of the immunological responses to a COVID-19 vaccine. She was a member of the Scientific Advisory Group for Emergencies, and provided the government with scientific advice during the pandemic.
NIDDM See: Non-insulin-dependent diabetes mellitus. Non-insulin-dependent diabetes mellitus (NIDDM) Out-of-date name for Type 2 diabetes mellitus. See: Type 2 diabetes mellitus. Noninvasive blood glucose monitoring A way to measure blood glucose without having to prick the finger to obtain a blood sample. Several noninvasive devices are currently being developed. Nonketotic coma A type of coma caused by a lack of insulin. A nonketotic crisis means: (1) very high levels of glucose (sugar) in the blood; (2) absence of ketoacidosis; (3) great loss of body fluid; and (4) a sleepy, confused, or comatose state. Nonketotic coma often results from some other problem such as a severe infection or kidney failure. NPH insulin A type of insulin that is intermediate-acting. Nutrition The proper levels of needed ingredients in the diet. Thus, '...his nutrition has been deficient in the past several weeks, as he is showing signs of scurvy, the deficiency disease associated with inadequate levels of vitamin C'. Nutritionist See: Dietitian.
Sources: en.wikipedia.org
93Zr is a radioisotope of zirconium with a half-life of 1.61 million years, decaying through emission of a low-energy beta particle. 73% of decays populate an excited state of niobium-93, which decays with a half-life of 13.9 years (almost entirely by internal conversion, emitting no gamma ray) to the stable ground state of 93Nb, while the remaining 27% of decays directly populate the ground state. It is one of the 7 long-lived fission products. The low specific activity and low energy of its radiation limit the radioactive hazards of this isotope, and its insolubility makes it unlikely to escape a waste repository; all these are shared with palladium-107. Nuclear fission produces it at a fission yield of 6.3% (thermal neutron fission of 235U), one of the most abundant fission products. Nuclear reactors usually contain large amounts of zirconium as fuel rod cladding (see zircalloy), and neutron irradiation of 92Zr also produces some 93Zr, though this is limited by 92Zr's low neutron capture cross section of 0.22 barns. Indeed, one of the primary reasons for using zirconium in fuel rod cladding is its low cross section. 93Zr also has a low neutron capture cross section of 0.7 barns. Most fission zirconium consists of other isotopes; the other isotope with a significant neutron absorption cross section is 91Zr with a cross section of 1.24 barns. 93Zr is a less attractive candidate for disposal by nuclear transmutation than are 99Tc and 129I.
== Related compounds == A dual DOR and κ-opioid receptor (KOR) PAM, BMS-986187, derived from BMS-986122, has been developed and is selective for these receptors over the MOR. Another MOR PAM with a simpler synthesis, MS1, was subsequently developed and has shown similar effects to those of BMS-986122. Additionally, ignavine, a natural MOR PAM found in Aconitum, has also been identified. In 2024, ketamine and its metabolites norketamine and hydroxynorketamine (HNK) were identified as highly potent MOR, DOR, and KOR PAMs (active at a concentration of as low as 1 nM). These actions were implicated in their potential antidepressant and analgesic effects.
The Beattie Ministry was a Ministry of the Government of Queensland, led by Labor Premier Peter Beattie. It commenced on 26 June 1998, thirteen days after the Borbidge Ministry, led by Premier Rob Borbidge of the National Party, was defeated at the 1998 election. It was followed by the Bligh Ministry upon Beattie's retirement as Premier on 13 September 2007.
The hypothalamic–pituitary–prolactin axis (HPP axis), also known as the hypothalamic–pituitary–mammary axis or hypothalamic–pituitary–breast axis, is a hypothalamic–pituitary axis which includes the secretion of prolactin (PRL; luteotropin) from the lactotrophs of the pituitary gland into the circulation and the subsequent action of prolactin on tissues such as, particularly, the mammary glands or breasts. It is involved in lobuloalveolar maturation of the mammary glands during pregnancy and the induction and maintenance of lactation following parturition. Hormones that control the secretion of prolactin from the pituitary gland include dopamine ("prolactin-inhibiting factor", or "PIF"), estradiol, progesterone, thyrotropin-releasing hormone (TRH), and vasoactive intestinal peptide (VIP).
==== Neurocognitive consequences ==== Similarly to children, OSA affects cognitive functions in adults. Meta-analysis have shown that the most common cognitive impairments happen in the domains of attention, verbal and visual delayed long-term memory, visuospatial/constructional abilities and executive functions, such as mental flexibility. The executive functioning – mainly dominated by the prefrontal cortex – being significantly impaired in patients with OSA, it is believed that the prefrontal region and its connectivity are affected by sleep disorders. Regarding memory deficits, verbal memory is significantly impaired as patients struggle with immediate and delayed verbal information recall. While meta-analyses have shown no deficits in information retention for patients with OSA, those impairments in verbal memory may be linked to problems in encoding information. This deficit in encoding of information is also noticed in visuo-spatial memory; however, the visual memory seems to be intact in OSA patients. The cognitive impairments have been suggested to result from sleep fragmentation and sleep deprivation, as well as the excessive daytime sleepiness associated with them. More precisely, attention and memory deficits seem to result from sleep fragmentation, while deficits in global cognitive function (executive function, psychomotor function, language abilities) are more related to hypoxia or hypercarbia, which accompanies the obstructive events during sleep.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.